ANNX
What one share of Annexon holds
Pharmaceutical Preparations
We are a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases that impact nearly 10 million people worldwide. The classical complement pathway is a core component to the body’s immune system that activates a powerful inflammatory cascade.
Annexon’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.13 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.07 |
| Cash and investments | $0.99 |
| Book value | $0.93 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$88.30 | $0.62 | −$66.03 | — | −$231.59 |
| 2020 | — | −$4.15 | $0.03 | −$3.16 | $0.00 | — |
| 2021 | — | −$3.40 | $0.04 | −$2.81 | $0.00 | $6.01 |
| 2022 | — | −$2.60 | $0.12 | −$2.25 | $0.00 | $4.84 |
| 2023 | — | −$1.77 | $0.00 | −$1.60 | $0.00 | $3.20 |
| 2024 | — | −$1.01 | $0.00 | −$0.86 | $0.00 | $2.68 |
| 2025 | — | −$1.34 | $0.00 | −$1.20 | $0.00 | $1.42 |